Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

(MedPage Today) -- MADRID -- Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news